Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Biogen-Abbott MS Drug Outperforms Placebo

October 24, 2011 6:52 am | News | Comments

Biogen Idec and Abbott Laboratories said a mid-stage study of their multiple sclerosis medicine daclizumab showed that the experimental drug worked better than placebo at preventing relapse of symptoms of the inflammatory disease.


Development of Autistic Brains Versus Healthy Brains

October 21, 2011 12:04 pm | News | Comments

Researchers at UCLA have found a possible explanation for why autistic children act and think differently than their peers.


Lisdexamfetamine Dimesylate Proves Effective for ADHD

October 21, 2011 12:00 pm | News | Comments

Shire announced positive results of a European Phase 3 study of once-daily lisdexamfetamine dimesylate in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder.


Target Identified To Decrease Triglycerides, Increase Cholesterol

October 21, 2011 11:32 am | News | Comments

Researchers announce findings that show the inhibition of both microRNA-33a and microRNA-33b with chemically modified anti-miR oligonucleotides suppress triglyceride levels and cause an increase in high density lipoprotein cholesterol.


Barcoded Tubes

October 21, 2011 8:05 am | Product Releases | Comments

Thermo Fisher Scientific Inc. introduced its Matrix Amber 2D barcoded tubes, expanding its sizeable sample storage product portfolio to offer protection of light-sensitive samples.


Supercritical Fluid Extractor

October 21, 2011 8:03 am | Product Releases | Comments

Supercritical Fluid Technologies, Inc.’s SFT-250 supercritical fluid extractor is designed to perform a variety of extractions in supercritical fluid and is engineered to meet the day-to-day rigors of the research lab.


Researchers Use T2MR to Detect Candida

October 21, 2011 7:53 am | News | Comments

Two independent groups from Massachusetts General Hospital and University of Houston College of Pharmacy used the T2MR platform to analyze whole blood specimens from patients with 5 different types of Candida spp. infections.


Sagent Bupivacaine Approved by FDA

October 21, 2011 7:48 am | News | Comments

Sagent Pharmaceuticals, Inc. announced U.S. FDA approval of bupivacaine hydrochloride injection, USP, a local or regional anesthetic. Sagent's bupivacaine will be available in six single-dose and two multi-dose latex-free vials.


Merck Reports Positive Boceprevir Results

October 21, 2011 7:44 am | News | Comments

Merck announced results from a Phase 2b study evaluating the investigational use of Victrelis in combination with peginterferon alfa and ribavirin for the treatment of chronic HCV genotype 1 infection in adult patients coinfected with HIV-1.


FDA Approves Watson Patch

October 21, 2011 7:22 am | News | Comments

Drugmaker Watson Pharmaceuticals Inc. said that the Food and Drug Administration has approved its testosterone patch Androderm in a smaller size and lower dose.


Hedge Fund Under SEC Microscope Over Cougar Deal

October 21, 2011 7:20 am | News | Comments

Hedge fund SAC Capital Advisors LP is being investigated by federal regulators for using inside information to profit from a health care takeover in 2009, the Wall Street Journal reported.


Amgen Likely to Highlight Sales Prospects

October 21, 2011 7:16 am | News | Comments

Amgen Inc., the world's largest biotech company by revenue, likely will focus on sales prospects for its top drugs and progress on its experimental drugs when it reports third-quarter results.


EU Opens Antitrust Probe into Novartis, J & J

October 21, 2011 7:12 am | News | Comments

The European Union is investigating whether drug companies Novartis and Johnson & Johnson colluded to keep a generic painkiller out of the Dutch market, the bloc's antitrust watchdog said.


Early HIV Treatment Increases Tuberculosis Patients Survival

October 20, 2011 12:38 pm | News | Comments

Starting HIV therapy in patients with both HIV and tuberculosis within two weeks of TB treatment increases survival by 33%.


Byetta Approved for Insulin Glargine Use

October 20, 2011 12:35 pm | News | Comments

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved a new use for Byetta (exenatide) injection.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.